Effectiveness of Infliximab vs. Biosimilar CT-P13 in Colitis Effectiveness of Infliximab vs. Biosimilar CT-P13 in Colitis

The infliximab biosimilar CT-P13 has been approved for the treatment of ulcerative colitis. Are they clinically equivalent in safety and efficacy?Alimentary Pharmacology & Therapeutics
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news